A gym inside the factory, a vegan menu and homemade dishes on the menu of the company restaurant, and a Montparnasse station poster campaign which is starting these days to promote the advantages of a job in Chartres: Novo Nordisk is recruiting and making it known. Specialist in drugs once morest diabetes, the pharmaceutical laboratory is preparing to create 150 jobs in 2022 on its site in Chartres (Eure-et-Loir). And in an employment pool that includes many industrialists, it is better to highlight its strengths.
As there are more and more diabetics in the world, the Chartres plant of the world leader in anti-diabetic care drugs is growing. The Danish industrialist is already the main private employer in the Eure-et-Loir department with a workforce of 1,200 employees. “It’s not easy to recruit because there is competition from other industries for the profiles of industrial operators and technicians, but Chartres attracts young people, especially those who want to leave Île-de-France to have living conditions that are more in line with their expectations,” explains Aurélien Levallet, the site’s human resources director, who recently signed employment contracts for employees from the Lyon area.
The Renewable Energy Argument
Partnerships exist with the IUT of Chartres, the branch of the Polytech Orléans engineering school, and the IMT (Institute of trades and technologies of medicine and cosmetics), which has just opened a school workshop in Dreux. . Despite this, Novo Nordisk is therefore seeking to attract employees from other regions. To convince them, the Danish laboratory highlights a few advantages. “We are managed by a foundation, which has a long-term vision,” explains Arnaud Dudermel, director of external relations.
Another argument, which is not insignificant: “We only use renewable energies. For young candidates, this is an argument that counts more and more, ”assures Aurélien Levallet. Already subscribed to green electricity, Novo Nordisk has just switched to biogas since the start of the year. In 2021, the Chartres plant produced injectable drugs for 8 million patients in 80 countries, with the aim of treating 10 million in a few years.
